Success Metrics

Clinical Success Rate
62.5%

Based on 5 completed trials

Completion Rate
63%(5/8)
Active Trials
0(0%)
Results Posted
20%(1 trials)
Terminated
3(30%)

Phase Distribution

Ph phase_1
5
50%
Ph phase_2
5
50%

Phase Distribution

5

Early Stage

5

Mid Stage

0

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
5(50.0%)
Phase 2Efficacy & side effects
5(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

50.0%

5 of 10 finished

Non-Completion Rate

50.0%

5 ended early

Currently Active

0

trials recruiting

Total Trials

10

all time

Status Distribution
Completed(5)
Terminated(5)

Detailed Status

Completed5
Terminated3
Withdrawn2

Development Timeline

Analytics

Development Status

Total Trials
10
Active
0
Success Rate
62.5%
Most Advanced
Phase 2

Trials by Phase

Phase 15 (50.0%)
Phase 25 (50.0%)

Trials by Status

terminated330%
withdrawn220%
completed550%

Recent Activity

0 active trials
Showing 5 of 10
terminatedphase_2

IPI-504 in NSCLC Patients With ALK Translocations

NCT01228435
withdrawnphase_2

Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated Liposarcoma

NCT00969917
completedphase_1

Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in KRAS Mutant Non-small Cell Lung Cancer

NCT01427946
completedphase_2

A Phase 2 Study to Investigate the Clinical Activity of IPI-504 in Patients With Hormone-resistant Prostate Cancer

NCT00564928
terminatedphase_2

Efficacy and Safety of IPI-504 With Trastuzumab Pretreated, Locally Advanced or Metastatic HER2 Positive Breast Cancer

NCT00817362
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT01228435Phase 2

IPI-504 in NSCLC Patients With ALK Translocations

Terminated
NCT00969917Phase 2

Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated Liposarcoma

Withdrawn
NCT01427946Phase 1

Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in KRAS Mutant Non-small Cell Lung Cancer

Completed
NCT00564928Phase 2

A Phase 2 Study to Investigate the Clinical Activity of IPI-504 in Patients With Hormone-resistant Prostate Cancer

Completed
NCT00817362Phase 2

Efficacy and Safety of IPI-504 With Trastuzumab Pretreated, Locally Advanced or Metastatic HER2 Positive Breast Cancer

Terminated
NCT00431015Phase 1

Phase I/II Safety Study of IPI-504 in Relapsed/Refractory Stage IIIb, or Stage IV Non-small Cell Lung Cancer (NSCLC)

Completed
NCT00627419Phase 2

A Study Evaluating the Safety and Antitumor Activity of IPI-504, in Patients With Metastatic Melanoma

Terminated
NCT00276302Phase 1

Safety Study of IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) or Soft Tissue Sarcomas (STS)

Completed
NCT00627627Phase 1

A Study to Evaluate the Antitumor Activity and Safety of IPI-504 in Patients With Advanced Breast Cancer

Withdrawn
NCT00113204Phase 1

Safety Study of IPI-504 in Patients With Relapsed and Relapsed Refractory Multiple Myeloma

Completed

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10